Molnupiravir, an Oral Antiviral Treatment for COVID-19

2021217 citationsPreprintgreen Open Access

Authors

William A. Fischer · University of North Carolina at Chapel Hill

Joseph J. Eron · University of North Carolina at Chapel Hill

Wayne Holman

Myron S. Cohen · University of North Carolina at Chapel Hill

Lei Fang

Laura J. Szewczyk

Timothy P. Sheahan · University of North Carolina at Chapel Hill

Ralph S. Baric · University of North Carolina at Chapel Hill

Abstract

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research SARS-CoV-2 detection and testing COVID-19 Clinical Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: medRxiv

DOI: 10.1101/2021.06.17.21258639